Case Report about Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test-Reference-Cited by-同舟云学术

Case Report about Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test

Published:2014-01 Issue: Volume:8 Page:CMO.S13897
ISSN:1179-5549
Container-title:Clinical Medicine Insights: Oncology
language:en
Short-container-title:Clin Med Insights Oncol

Author:

Dupont Benoît¹²,Mariotte Delphine³,Moldovan Cristian⁴,Grellard Jean-Michel⁵,Vergnaud Marie-Claude⁶,Laroche Dominique²⁷,Gervais Radj⁸

Affiliation:

1. CHU de Caen, Service d'Hépato-Gastroentérologie et Nutrition, Caen, France.

2. Université de Caen Basse-Normandie, UFR Médecine, Caen, France.

3. CHU de Caen, Laboratoire d'Immunologie et Immunopathologie, Caen, France.

4. Centre Henri Becquerel; Oncologie Médicale, Rouen, France.

5. Centre François Baclesse, Service de Recherche Clinique, Caen, France.

6. CHU de Caen; Service de Médecine Polyvalente, Caen, France.

7. CHU de Caen, Laboratoire d'Hormonologie, Caen, France.

8. Centre François Baclesse, Oncologie Médicale, Caen, France.

Abstract

Hypersensitivity reactions are a classic side effect of cetuximab. We report the cases of three patients who developed life-threatening hypersensitivity to cetuximab, which could have been predicted by assessing the concentration of serum anticetuximab immunoglobulin (Ig)E. The anti-cetuximab IgE concentration could be an interesting test to predict which patients are at risk of experiencing severe hypersensitivity reactions to cetuximab.

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.4137/CMO.S13897

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CACA guidelines for holistic integrative management of anticancer treatment - induced cutaneous adverse events;Holistic Integrative Oncology;2024-06-28

2. Innovative Metrics for Reporting and Comparing the Glycan Structural Profile in Biotherapeutics;Molecules;2023-04-07

3. Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab;BMC Cancer;2023-01-09

4. Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection;World Allergy Organization Journal;2021-07

5. Selective Intra-Arterial Chemoinfusion with Palliative Purpose in Patients with Relapses of Squamous Cell Carcinoma of the Head and Neck after Completed Chemoradiotherapy;Journal of oncology: diagnostic radiology and radiotherapy;2020-06-19